Clin Cancer Res 24:1062–1072ĭienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J (2017) Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani S, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris JS, Luthra R, Meric-Bernstam F, Overman MJ, Maru D, Kopetz S (2018) Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes.

BMC Cancer 16:554īaran B, Ozupek NM, Tetik YN, Acar E, Bekcioglu O, Baskin Y (2018) Difference between left-sided and right-sided colorectal cancer: a focused review of literature. Warschkow R, Sulz MC, Marti L, Tarantino I, Schmied BM, Cerny T, Güller U (2016) Better survival in right-sided versus left-sided stage I - III colon cancer patients. Petrelli F, Tomasello G, Borgonovo K, Ghidini M, Turati L, Dallera P, Passalacqua R, Sgroi G, Barni S (2017) Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. Meanwhile it is somewhat unexpected that the lower EGFR protein expression was found to be associated with better efficacy of anti-EGFR antibody therapies of colorectal cancer, the finding of which must be further validated. These data demonstrated for the first time that the EGFR protein expression is significantly higher in KRAS wild type RSLCL as compared to LSCRC. Although in case of progression-free survival data just indicated a trend ( p = 0.065), in case of overall survival the difference was significant favouring LSCRC ( p = 0.047). Kaplan Meyer survival analysis demonstrated that anti-EGFR antibody therapies were more effective in case of LSCRC compared to RSCRC. Furthermore, in a proportion of cases ( n = 31) metastatic tissues were also available and their analysis also found a significantly higher EGFR H-score in metastases of RSCRC compared to LSCRC ( p = 0.018). There was a significantly higher EGFR H-score detected in RSCRC as compared to LSCRC in primary tumors ( p = 0.04). In our cohort EGFR copy number, determined by FISH, was not associated with the level of EGFR protein, assessed by immunohistochemistry and measured by H-scoring. Here we have used a cohort of anti-EGFR antibody treated KRAS-wild type colorectal cancer patients ( n = 97) to analyse the prognostic role of EGFR protein expression in relation to sidedness. The role of EGFR protein expression in KRAS wild type colorectal cancer is also controversial.

Clinical data also indicate that they respond differently to anti-EGFR therapies. Right- and left-sided colorectal cancers (RSCRC and LSCRC, respectively) are different developmentally, genetically and prognostically.

Hepatic flexture of colon